Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST

AJR Am J Roentgenol. 2012 Apr;198(4):737-45. doi: 10.2214/AJR.11.7483.


Objective: The purpose of this article is to review cancer- and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case examples, and to discuss future directions toward "personalized" tumor response assessment.

Conclusion: Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer- and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / pathology*
  • Clinical Trials as Topic
  • Diagnostic Imaging*
  • Disease Progression
  • Humans
  • Immunotherapy / methods
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology*
  • Melanoma / drug therapy*
  • Melanoma / pathology*
  • Molecular Targeted Therapy / trends*
  • Outcome Assessment, Health Care / standards*
  • Precision Medicine*
  • Predictive Value of Tests
  • Prognosis


  • Angiogenesis Inhibitors